title: Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.
  
  
  METHODS
  Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).
  
  
  RESULTS
  There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.
  
  
  CONCLUSIONS
  The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.
authors.affiliation: Clinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Joelma Ines Tagliapietra
authors.initials: JI
authors.lastname: Barros
authors.affiliation: Clinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Francisco Vagnaldo
authors.initials: FV
authors.lastname: Fechine
authors.affiliation: Department of Community Health, School of Medicine, UFC, Fortaleza, CE, Brazil.
authors.forename: Renan Magalhães
authors.initials: RM
authors.lastname: Montenegro Júnior
authors.affiliation: Department of Clinical Medicine, School of Medicine, UFC, Fortaleza, CE, Brazil.
authors.forename: Otoni Cardoso do
authors.initials: OC
authors.lastname: Vale
authors.affiliation: University Hospital Walter Cantidio, UFC, Fortaleza, CE, Brazil.
authors.forename: Virgínia Oliveira
authors.initials: VO
authors.lastname: Fernandes
authors.affiliation: Department of Physiology and Pharmacology, School of Medicine, UFC, Fortaleza, CE, Brazil.
authors.forename: Marcellus Henrique Loiola Ponte de
authors.initials: MH
authors.lastname: Souza
authors.affiliation: Department of Nursing, UFC, Fortaleza, CE, Brazil.
authors.forename: Gilmara Holanda da
authors.initials: GH
authors.lastname: Cunha
authors.affiliation: Clinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Manoel Odorico de
authors.initials: MO
authors.lastname: Moraes
authors.affiliation: Clinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Catarina Brasil
authors.initials: CB
authors.lastname: d'Alva
authors.affiliation: Clinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Maria Elisabete Amaral de
authors.initials: ME
authors.lastname: Moraes
mesh_terms: D065767:Activation, Metabolic; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D019540:Area Under Curve; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects*; D005215:Fasting / Q000378:metabolism; D005260:Female; D005526:Food, Formulated; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D018709:Statistics, Nonparametric; D014230:Triazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000410:Alanine Transaminase; D001219:Aspartate Aminotransferases; D001786:Blood Glucose; D002784:Cholesterol; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles; D014280:Triglycerides; D005723:gamma-Glutamyltransferase